Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
about
Future therapeutic targets in rheumatoid arthritis?Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.Filgotinib for the treatment of rheumatoid arthritis.Efficacy of baricitinib in the treatment of rheumatoid arthritis.Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.Baricitinib: First Global Approval.The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis.Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.DNA methylation as a marker of response in rheumatoid arthritis.Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease.A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway.Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.The role of the JAK/STAT signal pathway in rheumatoid arthritis.Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System.Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implicationsStructural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
P2860
Q33841419-DF65F0D1-C61B-4B58-9A3D-E6872EA12576Q37728501-A95E618A-3403-4D78-9088-5633F9BB9684Q38372369-2E161D39-110D-47B5-8382-38EEE7DE2776Q38609755-24AEE4DD-C562-474D-B893-4CCC0418A43BQ38652849-081DFB94-90BC-4B92-BE0B-05E389207B84Q38932097-5A77EF11-D5BB-4367-9A11-78437F0AD630Q39020448-6214FEF1-344A-4BE0-8D36-9575C8909766Q39177156-168A5413-6D56-4847-AA54-60881E31DF62Q39215645-650D69B2-C2FE-4F82-8D7D-42F04F208214Q40267379-1DDC488C-7EC8-4EBE-B40A-371EC10AFAF7Q42701803-594B8287-FB17-46BC-93A8-41110A722AAEQ47118941-1D75C343-5910-48F2-9FB1-D0ED6817E5C2Q47153964-BEBFEFED-86B4-4BEF-B40D-9D1DA10109F4Q47439880-6F2E7CEE-07ED-4C92-878C-AEB35D35DA6DQ47602038-B9E60603-CAE3-47B2-BDD8-DD29B3169D5BQ48556502-38824419-FB56-4A7F-A212-21C18537E05CQ49587361-A09C5EDF-03F8-4AFC-BC09-FD9F041AA63FQ49792187-0889336F-5369-4146-A5E0-0BA6F9ADF446Q50323773-2A17A1BE-3AFD-4D17-8100-E4540B307813Q52536411-C29BDE3E-2FCC-42F4-8D52-790A402CD985Q52689527-1478B324-23F1-41C5-BEC7-A2920B6840E3Q53791793-A2DAB662-F3C8-4F05-8B3F-50E99E43CA0EQ54123254-8FFC7161-5F63-49AA-89A0-1F6C722858EEQ54977224-09744FA4-63E7-48F3-AE55-FFE16F0F995DQ55027042-EA498D05-1B86-4C6C-B1CF-964567601FBAQ55071760-97341161-2F19-4A9D-B85A-1E48D1E829AAQ55251974-F62DEFF7-364D-4FE9-80CC-18787F41A213Q55487787-00CC61B2-3761-4F46-A2AD-C6920A32D5D9Q55619613-A710F649-98E0-4827-BB99-B78031C923DCQ58774487-4921B4D5-B3AD-41CE-9E75-0D9A9B3D2A85Q58800533-306C3D1C-7A2F-4D88-A462-5338502F8C84
P2860
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@en
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@en-gb
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@nl
type
label
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@en
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@en-gb
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@nl
prefLabel
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@en
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@en-gb
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@nl
P2093
P2860
P50
P6366
P1154
2-s2.0-85027436891
P1476
Baricitinib in patients with i ...... sults from the RA-BUILD study.
@en
P2093
Carol Gaich
Douglas Schlichting
Edit Drescher
Inmaculada de la Torre
Jiajun Liu
Maria Greenwald
Sarah Witt
Scott Beattie
Stephanie de Bono
Terence Rooney
P2860
P356
10.1136/ANNRHEUMDIS-2016-210094
P407
P5530
P577
2016-09-29T00:00:00Z
P6179
1031221738
P6366
2525212149